New breast cancer trial aims to spare heart toxicity with smart drug strategy
NCT ID NCT07372079
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possible. The study aims to see if this approach can improve complete tumor disappearance before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (iparomlimab and tuvonralimab injection) combined with chemotherapy (albumin-bound paclitaxel, cisplatin, epirubicin, cyclophosphamide)
What this could lead to
If successful, this could offer a more personalized treatment for early triple-negative breast cancer, potentially reducing heart damage from chemotherapy while maintaining effectiveness.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and the response-guided approach may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••